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Abstract
Ethiopia is one of the sub-Saharan African countries contributing to the highest number of
maternal and neonatal deaths. Coverage of maternal and neonatal health (MNH) interventions has
remained very low in Ethiopia. We examined the cost-effectiveness of selected MNH interventions
in an Ethiopian setting. We analysed 13 case management and preventive MNH interventions. For
all interventions, we used an ingredients-based approach for cost estimation. We employed a static
life table model to estimate the health impact of a 20% increase in intervention coverage relative to
the baseline. We used disability-adjusted life years (DALYs) as the health outcome measure while
costs were expressed in 2018 US$. Analyses were based on local epidemiological, demographic
and cost data when available. Our finding shows that 12 out of the 13 interventions included in
our analysis were highly cost-effective. Interventions targeting newborns such as neonatal resusci-
tation (institutional), kangaroo mother care and management of newborn sepsis with injectable
antibiotics were the most cost-effective interventions with incremental cost-effectiveness ratios
of US$7, US$8 and US$17 per DALY averted, respectively. Obstetric interventions (induction of
labour, active management of third stage of labour, management of pre-eclampsia/eclampsia and
maternal sepsis, syphilis treatment and tetanus toxoid during pregnancy) and safe abortion cost
between US$100 and US$300 per DALY averted. Calcium supplementation for pre-eclampsia and
eclampsia prevention was the least cost-effective, with a cost per DALY of about US$3100. Many
of the MNH interventions analysed were highly cost-effective, and this evidence can inform the
ongoing essential health services package revision in Ethiopia. Our analysis also shows that
calcium supplementation does not appear to be cost-effective in our setting.
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Key Messages
• Most neonatal and obstetric interventions are highly cost-effective in an Ethiopian setting.
• Neonatal resuscitation and kangaroo mother care were the most cost-effective interventions while calcium supplementa-
tion was the least cost-effective among the 13 interventions included in our analysis.
• The evidence can inform the ongoing essential health services package revision in Ethiopia.
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Introduction
With 11 000 women dying during pregnancy or childbirth, Ethiopia
is one among the 10 countries that contribute to 60% of the global
maternal deaths estimated in 2015 (Trends in maternal mortality:
1990 to 2015, 2015). Even though Ethiopia has witnessed a signifi-
cant decline in under-five mortality (Central Statistical Agency
(CSA) [Ethiopia] and ICF, 2016); the proportion of under-five
deaths that occur during the first 28 days of life is increasing.
Neonatal deaths accounted for 30% and 43% of under-five deaths
in the 2000 and 2016 Demographic and Health Surveys (DHS), re-
spectively (Central Statistical Agency (CSA) [Ethiopia] and ICF,
2001, 2016). Ethiopia is among the five sub-Saharan African coun-
tries contributing to the highest number of neonatal deaths, with
>90 000 deaths in 2016 (Levels and Trends in Child Mortality,
2017).
Maternal and neonatal deaths arise from the risks attributable to
pregnancy and childbirth as well as from low coverage and poor-
quality health services (Freedman et al., 2005). Effective interven-
tions during the antenatal period, the time around birth, and the first
week of life that can significantly decrease maternal and neonatal
deaths are available (Trends in maternal mortality: 1990 to 2015,
2015; Levels and Trends in Child Mortality, 2017), but their cover-
age levels have remained very low in Ethiopia: coverage of skilled
birth attendance and post-natal visits (within 2 days of birth), were
in 2015 28% and 13%, respectively (Central Statistical Agency
(CSA) [Ethiopia] and ICF, 2016).
Maternal and child health has been the focus of both the
Millennium Development Goals and sustainable development goals
(SDGs) (Sustainable Development Knowledge Platform, 2018). SDG
targets 3.1 and 3.2 for maternal and child mortality represent a
transformative new agenda towards ending preventable maternal
and child deaths globally; all countries aiming to reduce maternal
deaths to 70 per 100 000 live births and neonatal mortality to 12
per 1000 live births by 2030 (Sustainable Development Knowledge
Platform, 2018). The Ministry of Health of Ethiopia intends to
achieve population health levels commensurate with the average of
lower middle-income countries in 2025 and upper middle-income
countries in 2035 (Admasu et al., 2014). The national targets set are
in line with the SDGs targets for maternal and neonatal deaths.
Achievement of these targets requires scale-up of high impact and
cost-effective maternal and neonatal interventions in Ethiopia. This
is particularly important given the resource scarcity in Ethiopia as
evidenced by the sixth National Health Accounts, which reported
Ethiopia’s total health expenditure per capita at about US$30 for
the years 2013/14 (Federal Democratic Republic of Ethiopia
Ministry of Health, 2017).
Cost-effectiveness analysis (CEA) in the evaluation of health de-
livery has become an increasingly accepted component of health pol-
icy and planning (World Health Organization, 2010). Experience
from several countries, however, has shown that CEA results are
rarely used to inform policy decision-making largely due to lack of
contextualized evidence (Tan-Torres Edejer et al., 2003). Absence of
local data on estimates of cost and effectiveness of health interven-
tions leads health planners to use evidence generated elsewhere,
often from a setting different to the local one. However, studies
have shown that several factors may alter the actual cost-
effectiveness of a given intervention across settings (Hutubessy
et al., 2003). Evidence on cost-effectiveness of interventions to im-
prove maternal and neonatal health (MNH) outcomes in developing
countries is scarce and to our knowledge non-existent in Ethiopia.
In this article, we examine the cost-effectiveness of selected
MNH interventions in an Ethiopian setting. The evidence generated




We evaluate 13 MNH interventions that are provided during preg-
nancy, childbirth and the neonatal period (Table 1). Interventions
were selected based on expert recommendations and scientific evi-
dence of benefit to maternal and neonatal survival (Blencowe et al.,
2010; Cousens et al., 2010; Lawn et al., 2010; Mwansa-Kambafwile
et al., 2010; Blencowe et al., 2011; Hussain et al., 2011; Imdad
et al., 2011; Jabeen et al., 2011; Lee et al., 2011; Pollard et al.,
2013; Ronsmans and Campbell, 2011; Zaidi et al., 2011). The inter-
ventions included were: safe abortion; interventions during preg-
nancy [tetanus toxoid, syphilis detection and treatment, calcium
supplementation, management of pre-eclampsia and eclampsia,1
antibiotics for preterm pre-labour rupture of membrane (pPRoM),
antenatal corticosteroids for preterm labour, induction of labour];
intrapartum interventions (active management of the third stage of
labour); post-partum interventions (maternal sepsis case manage-
ment, newborn sepsis management, neonatal resuscitation and kan-
garoo mother care). These interventions were selected because they
had the most data available, target the most important maternal and
neonatal disease conditions in Ethiopia and were among the nation-
al priorities of the Ethiopia’s ministry of health (Federal Democratic
Republic of Ethiopia Ministry of Health, 2015). Most of these inter-
ventions, except calcium supplementation, are part of the essential
services rendered in public health facilities in Ethiopia though their
coverage is very low (Table 1). For safe abortion services and tet-
anus toxoid baseline coverage data were extracted from the Health
Sector Transformation Plan and the 2016 Ethiopia Health and
Demographic Survey, respectively (Federal Democratic Republic of
Ethiopia Ministry of Health, 2015; Central Statistical Agency [CSA]
[Ethiopia] and ICF, 2016), but for the other interventions, we used
baseline coverage rates from the Lives Saved Tool (LiST) (Avenir
Health, 2017). Given the low coverage of interventions, we set mod-
est target coverage with a 20 percentage points increase from the
baseline of all the interventions.
Intervention effectiveness and health impacts
Efficacy data were based on available evidence in accordance with a
recent update for LiST (Blencowe et al., 2010; Cousens et al., 2010;
Lawn et al., 2010; Mwansa-Kambafwile et al., 2010; Blencowe
et al., 2011; Hussain et al., 2011; Imdad et al., 2011; Jabeen et al.,
2011; Lee et al., 2011; Ronsmans and Campbell, 2011; Zaidi et al.,
2011; Pollard et al., 2013). We used LiST to determine cause-
specific neonatal and maternal deaths associated with diseases/con-
ditions for the baseline coverage levels. LiST combines national
inputs on age-specific population size, disease incidence, prevalence
and mortality to calculate the number of maternal and neonatal lives
saved for a given set of interventions at a specified increase in cover-
age (Boschi-Pinto et al., 2010). The number of cause-specific deaths
that would be prevented for a change in the coverage of a given
intervention would be calculated as (Winfrey et al., 2011):
Deaths prevented ¼ NI P1 P0
ð ÞAF
ð1 IP0Þ ; (1)
where, N is the number of deaths at baseline coverage, I is the
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intervention effectiveness, P0 is the baseline intervention coverage,
P1 is the intervention target coverage, AF is the attributable fraction
(fraction of the adverse condition such as death that is attributable
to a specific exposure). Table 2 presents cause-specific neonatal and
maternal outcomes, related baseline deaths, attributable fractions
and intervention effectiveness. Once the number of deaths prevented
by each intervention was estimated, the disability-adjusted life years
(DALYs) averted were also computed, based on the life table for
Ethiopia adjusted by health state valuations from the World Health
Organization cost-effectiveness and strategic planning (WHO-
CHOICE) data for the African region (World Health Organization,
2018a and 2018b). DALYs averted by each intervention were then
calculated as the sum of deaths preventable at each age, multiplied
by disability-adjusted life expectancy at that age, which were dis-
counted at 3% per year (Tan-Torres Edejer et al., 2003).
Costs
Costs are estimated from the provider’s perspective and only direct
medical costs borne by the provider at the point of service delivery
were included. Costs were divided into patient- and programme-
level costs. Patient-level costs included: drugs, supplies, laboratory,
outpatient visits, inpatient stays and individual health education
messages. Programme-level costs included resources to establish and
maintain an intervention: administration, publicity, training and
delivery of supplies.
To calculate costs, we used an ingredients approach that requires
information on the quantities of inputs needed and their unit price
(details of cost computation are presented in Supplementary Data).
Costs were computed by multiplying quantities of inputs with their
unit price. The quantities of resources used for the interventions
were based on WHO-CHOICE assumptions (Table 1). Unit costs
for hospital and health centre visits and hospital bed-day costs were
extracted from WHO-CHOICE (World Health Organization,
2018c). Costs for laboratory tests were collected from several gov-
ernment health facilities. We used the average value of the labora-
tory cost depending on the level of service delivery. For drugs and
supplies that are traded internationally, we used the median supplier
price available internationally in 2015 (Table 3) with adjustment to
include transportation costs (Joint Medical Store, 2014;
Management Science for Health, 2016). We estimated programme-
level costs to be 10% of patient-level costs, based on a previous
study in Ethiopia (Mathewos et al., 2017). We used the same pro-
gramme-level costs across interventions, which is 10% of the aver-
age patient-level cost of all interventions included in our analysis.
Table 1 Interventions included in the analysis, their description, target population, baseline and target coverage rates
Intervention Description of the intervention
(number of visits)














Screening of all pregnant women by RPR
test and treatment of identified cases with
benzathine penicillinb (one visit)
All pregnant women during
ANC visit
31 51
Calcium supplementation Routine calcium supplementation during
pregnancyb (one visit)





Package of care including anti-hypertensives
and magnesium sulfatesb (three hospital
bed days)
Women with pre-eclampsia
(2.8% of births) and
eclampsia (1%)
3 23
Antibiotics for pPRoM Administration of oral antibiotics to women
with pPRoMb (two hospital bed days)





Administration of steroids and inpatient care
of women with suspected preterm labourb
(two hospital bed days)
Women with premature labour
(10.1% of births)
0 20
Active management of the
third stage of labour
Administration of prophylactic oxytocin,
cord clamping and delivery of the placenta
by controlled cord tractionb
All pregnant women 23 43
Induction of labour (beyond
41 weeks)
Induction of labour at 41 weeks gestation
with 200 lg misoprostolb
Women at gestational age




Development of sepsis within the 42 days
following delivery, requiring inpatient
care including treatment with antibioticsb
(four hospital bed days)
Women with infection within





Detection of breathing problems and
resuscitation if required
Births with asphyxia (1% of
births)
26 46
Newborn sepsis Administration of IV/IM antibiotics for neo-
natal sepsis, meningitis, or pneumoniab
Neonates with infection (10% of
births)
26 46
Kangaroo mother care Thermal care for newborn babies weighing
<2000 g through continual skin to skin
contact (1 visit)
Low birth weight babies (15% of
births)
22 42
aTarget coverage is an increase in 20% coverage points from the baseline.
bDetails of the drug regimen, other supplies and laboratory cost are provided in Web Appendix I.
IV/IM, intravenous/intramuscular; pPRoM, preterm pre-labour rupture of membrane; RPR, rapid plasma reagin.
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Direct non-medical costs (e.g. transportation) and indirect costs to
patients and caregivers such as lost productivity were not included
in the analysis. Total cost was the sum of patient- and programme-
level costs. Costs were reported in 2018 US$.
Estimation of cost-effectiveness
We assessed the cost and health effects on the population of the
interventions scale-up compared with the current coverage scenario.
We opted to use the current coverage levels for the following rea-
sons: (1) most of the interventions were part of the health services
package though their coverage rates were very low, ranging from
0% to 49%; (2) For the current coverage levels, baseline mortality
data were available from the LiST tool; (3) The current coverage
level could impact the magnitude of incremental health benefits of
intervention scale-up and subsequently the incremental cost-
effectiveness ratios (ICERs); and (4) The policy relevance is likely
higher when ICERs are estimated from the current coverage rates.
ICERs were estimated dividing the incremental cost by incremental
health effects of each intervention for the 20 percentage points
coverage increase. Comparing the cost of the intervention with the
gain in health could then be used to identify the most cost-effective
sets of interventions. ICERs are reported in US$ per DALY averted
for the year 2018.
Uncertainty analysis
Given the uncertainty surrounding intervention costs and effective-
ness inputs, we conducted a probabilistic uncertainty analysis with
Monte Carlo simulations to assess the robustness of our findings
(Baltussen et al., 2002). We used a truncated normal distribution for
both costs and effects with 15–25% standard deviations and pro-
ceeded to n¼1000 simulation runs. We also conducted one-way
sensitivity analyses where we varied the inputs as follows: applying
50% of the effectiveness estimates; doubling the price of drugs, sup-
plies and laboratory tests; no discounting of health benefits; and
75% adherence to treatment.
Results
Annual intervention costs, DALYs averted, and ICERs associated
with a 20% coverage increase are shown in Table 4. Kangaroo
mother care, neonatal resuscitation (institutional), antibiotics for
preterm pre-labour rupture of membrane, antenatal corticosteroids
for preterm labour and injectable antibiotics for newborn sepsis cost
Table 2 Intervention effectiveness on neonatal and maternal mortality and attributable fractions (of deaths)
Intervention Neonatal outcome























































Active management of the



















Deaths from neonatal sepsis
(12 292)
65 1
Deaths from neonatal pneu-
monia (5876)
75 1
Kangaroo mother care Deaths from prematurity
(15 450)
40 1
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<US$100 per DALY averted. Induction of labour, safe abortion,
management of pre-eclampsia/eclampsia, maternal sepsis case
management, syphilis detection and treatment during pregnancy,
active management of third stage of labour and tetanus toxoid dur-
ing pregnancy cost between US$100 and US$300 per DALY
averted. The ICER for Calcium supplementation is 3100 per
DALY averted, which is 4.4 times the gross domestic product
(GDP) per capita in Ethiopia. For all other interventions, the
ICERs are less than US$300 per DALY averted, which is <0.4
times the GDP per capita in Ethiopia. The ICERs suggest that inter-
ventions for newborn care are highly cost-effective. Neonatal re-
suscitation, Kangaroo mother care and newborn sepsis
management are all estimated to provide 1 DALY averted for a
cost of less than US$20.
Implementation of all 12 individual interventions (except cal-
cium supplementation) for a 20% point increase in coverage would
Table 3 Unit cost inputs and socio-demographic data
Description Unit prices, median (US$) Description Unit prices, median (US$)
Drugs and supplies (source: Management Science for Health, 2016)
Misoprostol 200 mg (TAB/CAP) 0.1810 Amoxicillin suspension, 1 BOTT 0.4600
Paracetamol, 500 mg (TAB/CAP) 0.0044 Betamethasone 4 mg/ml (INJ) 0.2503
Tetanus toxoid vial (INJ) per dose 0.6869 Oxytocin 10 IU AMP (INJ) 0.1557
Benzanthine Pn 2.4 MU vial (INJ) 0.2612 Ampicillin 500 mg vial (INJ) 0.1507
Calcium Lactate 300 mg (TAB/CAP) 0.0129 Gentamicin 80 mg AMP (INJ) 0.0600
Sodium lactate solution, 500 ml (IV) 0. 5000 Gentamicin 20 mg AMP (INJ) 0.1760
MgSO4 5 g/10 ml vial (INJ) 0.7340 Metronidazole 500 mg vial (INJ) 0.5000
Lidocaine 2 ml AMP (INJ) 0.0972 Ceftriaxone 250 mg vial (INJ) 0.3538
Hydralazine, 20 mg AMP (INJ) 3.8578 Foley catheter, ch 14a 0.5662
Erythromycin 250 mg (TAB/CAP) 0.0306 Urine bag, 2 La 0.3700
Amoxicillin 500 mg (TAB/CAP) 0.0300 Infant Bag and Maskb 20.44
Syphilis RPR (DIAG) per test 0.1250
Healtd service delivery costs (source: World Health Organization, 2018c)
Hospital (cost per visit) 1.59 Health centre (cost per visit) 1.96
Hospital (cost per bed day) 4.04
Laboratory tests and procedures
Complete blood count 1.98 CSFc 8.42
Blood culture and sensitivity 1.5
Socio-demographic data
Total population in 2018 107.5 million United Nations Population Division (2017)
Live births in 2018 3.34 million FMoH (2017)d
GDP per capita ($US) 707 The World Bank (2016)
GDP per capita, PPP (Int.$) 1735 The World Bank (2016)
Official exchange rate (ETB per $US) 27.5 NBE (2018)e
aSource: Joint Medical Store (2014).
bSource: https://www.laerdal.com/no/Search.aspx? q¼BagþandþMask.
cIncludes the cost of lumbar puncture, cerebrospinal fluid analysis, culture and sensitivity.
dSource: The Government of Federal Democratic Republic of Ethiopia (2017).
eSource: National Bank of Ethiopia (2018).
Table 4 Cost, effects and cost-effectiveness for a 20% points increase in coverage of maternal and neonatal interventions in Ethiopia in 2018
No. Intervention Total cost US$ (millions) DALYs averted (millions) ICER (US$
per DALYs averted)
Discounted Undiscounted
1 Kangaroo mother care 0.29 0.037 0.074 8
2 Neonatal resuscitation (institutional) 0.36 0.055 0.110 7
3 Induction of labour (beyond 41 weeks) 0.39 0.003 0.005 152
4 Management of pre-eclampsia and eclampsia 0.52 0.005 0.008 108
5 Antibiotics for preterm pre-labour rupture of membrane (pPRoM) 0.59 0.009 0.017 69
6 Safe abortion 0.74 0.007 0.011 108
7 Antenatal corticosteroids for preterm labour 0.84 0.009 0.017 98
8 Newborn sepsis—injectable antibiotics 0.91 0.052 0.105 17
9 Maternal sepsis case management 1.15 0.005 0.009 220
10 Syphilis detection and treatment (pregnant women) 1.52 0.007 0.014 224
11 Active management of the third stage of labour 1.62 0.007 0.011 245
12 Tetanus toxoid (pregnant women) 2.69 0.016 0.032 168
13 Calcium supplementation 4.95 0.002 0.003 3081
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avert nearly 8000 neonatal deaths (11% reduction from baseline)
and >1000 maternal deaths (10% reduction from baseline) at
the cost of nearly US$12 million annually. Neonatal resuscitation,
newborn sepsis management and kangaroo mother care would con-
tribute to 80% of the neonatal deaths averted (nearly 6400 deaths)
at a cost of nearly US$1.6 million.
Table 5 summarizes the results of the one-way sensitivity analy-
ses of individual interventions and shows the substantial uncer-
tainty that resides within the cost-effectiveness estimates. Including
undiscounted health benefits halves the ICER of all interventions
making all interventions more cost-effective. However, decreasing
the intervention effectiveness by 50% doubles the ICERs of inter-
ventions. Doubling the cost of drugs, supplies and laboratory
increased the ICERs 1.6 to 2 times higher as compared with the
base-case. Despite such variations, all the interventions except cal-
cium supplementation, remain at an ICER <US$500 per DALY
averted. The most important cost driver for calcium supplementa-
tion was the drug cost, which accounted to 77% of the interven-
tion’s total cost. Figure 1 shows the result of probabilistic
sensitivity analysis. It illustrates the considerable uncertainty sur-
rounding our cost-effectiveness estimates, with wide and overlap-
ping cost and effectiveness ranges.
Discussion
Our analysis showed that 12 out of the 13 MNH interventions were
highly cost-effective. All interventions that are included in our analysis
(except calcium supplementation that is not yet implemented in public
health facilities) are not entirely new to the Ethiopian health system.
However, most of the interventions have a very low coverage rate.
Therefore, assessing the cost-effectiveness of interventions that are cur-
rently implemented as well as adding those that could potentially be
introduced can assist policymakers and planners in Ethiopia to priori-
tize the unfinished agenda of MNH. All interventions, besides calcium
supplementation, were found to be very cost-effective (<US$300 per
DALY) in Ethiopia. Adam et al. (2005) have reported a similar pattern
to what we found in their CEA of strategies for MNH in developing
countries (calcium supplementation and safe abortion were not
included in their analysis however). A study conducted on the cost-
effectiveness of calcium supplementation in Colombia concluded that
varying the cost of calcium tablets or the incidence of pre-eclampsia
renders the intervention no longer cost-effective for a threshold of
three times Colombia’s GDP per capita (Becerra et al., 2012).
Our results demonstrate that the interventions that could be
delivered at the primary health care (PHC) level were very cost-
Table 5 ICERs for maternal and neonatal interventions under multiple scenarios







1 Induction of labour (beyond 41 weeks) 152 76 229 256 306
2 Kangaroo mother care 8 4 12 12 16
3 Neonatal resuscitation (institutional) 7 3 10 11 13
4 Management of pre-eclampsia and eclampsia 108 65 162 189 217
5 Antibiotics for preterm pre-labour rupture of membrane (pPRoM) 69 35 104 124 139
6 Safe abortion 108 70 162 197 216
7 Antenatal corticosteroids for preterm labour 98 49 147 181 196
8 Newborn sepsis—injectable antibiotics 17 9 26 32 35
9 Maternal sepsis case management 220 133 330 415 440
10 Syphilis detection and treatment (pregnant women) 224 107 336 430 449
11 Active management of the third stage of labour 245 148 367 470 489
12 Tetanus toxoid (pregnant women) 168 84 252 328 336


























Annual health benefits (in million DALYs averted)
Neonatal resuscitation (institutional)
Induction of labor  (beyond 41 weeks)
Kangaroo mother care
Management of pre-eclampsia and eclampsia
Safe abortion
Antibiotics for pPRoM
Syphilis detection and treatment
Maternal Sepsis case management
Active management of the 3rd stage of labour
Newborn sepsis - Injectable antibiotics
Tetanus toxoid
Antenatal corticostero ids for preterm labor
Calcium supplementation
Figure 1 Probabilistic sensitivity analysis of MNH interventions in Ethiopia.
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effective. In the last decade, Ethiopia has introduced a health exten-
sion programme with the training and deployment of >38 000
health extension workers (HEWs) which represents an opportunity
to scale-up MNH interventions at the community level (Federal
Democratic Republic of Ethiopia Ministry of Health 2015; Federal
Ministry of Health of Ethiopia 2007). HEWs could indeed play im-
portant roles such as identifying pregnant women and teaching them
to identify complications that arise during pregnancy and respond-
ing immediately; or providing post-delivery follow-up care for the
mother infant pair. Management of neonatal infection with antibiot-
ics and community care of newborns were found to be effective in
reducing neonatal mortality and scalable at the community level
(Baqui et al., 2009; Traa et al., 2010). Furthermore, a programme
intervention study conducted in the Southern part of Ethiopia (using
a ‘continuum of care’ approach) to evaluate the delivery of essential
antenatal and obstetric services in communities through HEWs
resulted in a significant decline in both maternal deaths and still-
births highlighting the feasibility and effectiveness of maternal and
neonatal interventions in Ethiopia (Lindtjørn et al., 2017, 2018).
Delivery of services at the community level using HEWs has the add-
itional benefit of bringing care to all women and infants, particular-
ly to those socio-economically disadvantaged and marginalized
rural residents. In our analysis, kangaroo mother care that was
offered in neonatal facilities was very cost-effective (US$8 per
DALY averted). Perhaps the introduction of KMC along with
breastfeeding support for preterm/low birth weight newborns at the
community level may even be a more cost-effective alternative than
providing this service in neonatal wards.
Safe abortion care is one of the cost-effective services that can be
delivered effectively at PHC facilities. The cost of treatment from
the provider perspective to provide safe abortion using the medical
method (vaginal misoprostol) for a single case was US$10 in Ghana,
which is comparable to our estimate of an average cost per patient
close to US$8 (Hu et al., 2010). Safe abortion at the health centre
level, such as manual vacuum aspiration or medical abortion using
misoprostol resulted in substantial cost savings as compared with
dilatation and curettage that is often hospital based. Most public
health centres in Ethiopia are not currently providing safe abortion
services (Federal Democratic Republic of Ethiopia Ministry of
Health, 2015). The broadening of legal indications for abortion (the
2005 revised family law of Ethiopia) and the issuance of safe abor-
tion technical guideline in 2006 created a favourable environment to
scale-up delivery of safe abortion services in Ethiopia.
Despite the fact that most of the interventions delivered at the
community level and in PHC facilities are very cost-effective, pre-
vention of most maternal and neonatal deaths requires access to
quality clinical care services. Improving quality of care is often con-
sidered very costly. However, a research project by the prevention of
maternal mortality network in West Africa found that renovation or
upgrading of essential obstetric care services in district hospitals and
health centres was not as expensive as often assumed. Most develop-
ing countries have extensive health systems that are often under-
utilized. With inputs such as opening operating rooms with a supply
of electricity and blood banks, for less than $15 000, improvement
in the provision of quality delivery care services with significant im-
pact on maternal mortality have been seen (Prevention of Maternal
Mortality Network, 1997). Ethiopia has undertaken an accelerated
expansion of PHC facilities since 2003 and currently there are
>3300 functional health centres that could serve as important inputs
in the scale-up of obstetric care in Ethiopia (Federal Democratic
Republic of Ethiopia Ministry of Health, 2015). Additionally, deliv-
ery of quality obstetric and neonatal services requires a reliable
supply of medicines, functioning equipment and respectful provider
attitude (Kruk et al., 2010). Cultural factors also influence utiliza-
tion of facility delivery care services. According to 2014 Ethiopian
Mini DHS, 34% of rural women reported that facility deliveries
were not customary highlighting the need for enhanced community
mobilization (Central Statistical Agency, 2014).
The study has several limitations. First, our analysis does not in-
clude all possible maternal and neonatal interventions that could be
considered in Ethiopia. Additional analysis may therefore be war-
ranted. Second, the efficacy data we used were derived from studies
conducted in more developed countries with higher quality of serv-
ices and may not translate directly to Ethiopia. In the analysis of
cost, we have included patient- and programme-level intervention
costs that are incremental to the current coverage levels and fail to
address the cost required for facility expansion. Data on perinatal
mortality were not included in the analysis that may result in under
estimation of the cost-effectiveness of interventions such as syphilis
case detection and treatment. Due to the possibility of interactions
in both cost and health impacts of implementing several single inter-
ventions at once; it is likely that the deaths averted could have been
overestimated.
Despite these limitations, our findings can guide future health
sector planning in Ethiopia. Along with the government’s vision
to become a middle-income country, the Ministry of Health of
Ethiopia has set ambitious health targets (Admasu et al., 2014). The
key strategy is ensuring universal access of basic health interventions
for all Ethiopians mainly through strengthening PHC. The base-case
scenario targets in Ethiopia for 2025 includes; a maternal mortality
ratio of 260 per 100 000 live births, neonatal mortality rate of 28
per 1000 live births and 77% coverage for four antenatal care visits
and skilled birth attendance. Even though our analysis considered a
20% point increase in coverage in a year, further scale-up of all indi-
vidual interventions (excluding calcium supplementation) to the tar-
get coverage rates as set in the envisioning document will likely
contribute to the achievement of maternal and neonatal mortality
targets. The annual budget required to implement a 20% increase in
coverage of all the 12 individual interventions costs an additional
0.11 US$per capita which is 0.46% of the 2013/14 annual total
health expenditure (2.52 billion US$) for Ethiopia. In comparison,
according to a study on CEA of cardiovascular diseases interven-
tions in Ethiopia, combination of drug treatment for absolute risk of
cardiovascular diseases >35% (which had the lowest ICER, 67
US$per DALYs averted) was estimated to cost 0.4% of the 2010/11
annual total health expenditure (1.6 billion US$) and averts about
107 000 DALYs (Tolla et al., 2016). Similarly, a CEA of mental
health interventions showed a 2.1% increase in annual total health
budget (2012) would be required to implement the mental health
interventions in Ethiopia with an expected health gain of 197 000
healthy life years (Strand et al., 2015).
While evidence on cost-effectiveness is an important tool in pri-
oritizing health interventions, it should not be the only consideration
in the selection of interventions for implementation in a country.
The priority setting process should also consider other socially desir-
able goals and major health system objectives such as equity and fi-
nancial risk protection (World Health Organization, 2014). For
example, most interventions included in our analysis could be fur-
ther evaluated in terms of the gains in financial risk protection they
bring to Ethiopian families (e.g. reduction in medical impoverish-
ment related to maternal and child health conditions) (Johansson
et al., 2015; Pecenka et al. 2015; Verguet et al., 2016; Memirie
et al., 2017). In this respect, many of the interventions examined in
this article could be delivered at PHC facilities bringing care nearer
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to rural women and infants where most of the poorer Ethiopians res-
ide (Moges, 2013).
Conclusions
Given the substantial health dividend from investing in universal
coverage of the intervention included in our analysis, this evidence
could inform national policymakers to prioritize scale-up of mater-
nal and child health interventions in Ethiopia. It can also inform the
ongoing essential health services package revision in Ethiopia. Our
analysis also suggests that calcium supplementation may not be pri-
oritized for inclusion in Ethiopia’s essential MNH intervention
package.
Note
1. Even though the management of pre-eclampsia/eclampsia
could start during pregnancy it will usually continue during la-
bour and delivery.
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